BG104643A - 2, 3-заместени индолови съединения като инхибитори на сох-2 - Google Patents

2, 3-заместени индолови съединения като инхибитори на сох-2 Download PDF

Info

Publication number: BG104643A
Authority: BG; Bulgaria
Prior art keywords: indol; chloro; acetic acid; carbonyl; alkyl
Prior art date: 1998-01-05

Application number

BG104643A

Other languages

Bulgarian (bg)

English (en)

Inventor

Kazunari Nakao

Rodney Stevens

Kiyoshi Kawamura

Chikara Uchida

Hiroki Koike

Stephane Caron

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-05

Filing date

2000-07-28

Publication date

2001-02-28

2000-07-28 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2001-02-28 Publication of BG104643A publication Critical patent/BG104643A/bg

Links

150000002475 indoles Chemical class 0.000 title description 8
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title description 7
229940111134 coxibs Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 209
125000005843 halogen group Chemical group 0.000 claims abstract description 159
125000004414 alkyl thio group Chemical group 0.000 claims abstract description 149
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 138
125000005842 heteroatom Chemical group 0.000 claims abstract description 66
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 63
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 57
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 52
229910052717 sulfur Inorganic materials 0.000 claims abstract description 34
229910052760 oxygen Inorganic materials 0.000 claims abstract description 29
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 28
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
239000001257 hydrogen Substances 0.000 claims abstract description 27
238000011282 treatment Methods 0.000 claims abstract description 24
150000003180 prostaglandins Chemical class 0.000 claims abstract description 15
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
229940094443 oxytocics prostaglandins Drugs 0.000 claims abstract description 12
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 11
244000052769 pathogen Species 0.000 claims abstract description 6
125000000217 alkyl group Chemical group 0.000 claims description 760
229910052736 halogen Inorganic materials 0.000 claims description 424
-1 dimethylamino, methylamino, amino Chemical group 0.000 claims description 379
125000003545 alkoxy group Chemical group 0.000 claims description 330
150000002367 halogens Chemical class 0.000 claims description 302
125000001424 substituent group Chemical group 0.000 claims description 257
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 243
125000003282 alkyl amino group Chemical group 0.000 claims description 150
238000000034 method Methods 0.000 claims description 108
125000003118 aryl group Chemical group 0.000 claims description 94
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 90
125000000753 cycloalkyl group Chemical group 0.000 claims description 75
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 59
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 58
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 54
239000002904 solvent Substances 0.000 claims description 50
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 48
229910000027 potassium carbonate Inorganic materials 0.000 claims description 45
235000011181 potassium carbonates Nutrition 0.000 claims description 45
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 44
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 44
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 42
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 38
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 36
229910000024 caesium carbonate Inorganic materials 0.000 claims description 36
238000006243 chemical reaction Methods 0.000 claims description 36
125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims description 33
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 31
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 30
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 30
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 27
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 27
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 26
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 25
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 24
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 22
229910000029 sodium carbonate Inorganic materials 0.000 claims description 22
235000017550 sodium carbonate Nutrition 0.000 claims description 22
HQRJGLVSBRTHME-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)acetic acid Chemical class N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 HQRJGLVSBRTHME-UHFFFAOYSA-N 0.000 claims description 21
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 21
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 21
125000006239 protecting group Chemical group 0.000 claims description 21
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 21
ZVWYMLHJDRBVDP-UHFFFAOYSA-N 2-[6-chloro-2-(5-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=N1 ZVWYMLHJDRBVDP-UHFFFAOYSA-N 0.000 claims description 19
239000000460 chlorine Substances 0.000 claims description 19
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 18
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
XVLQJDCWMUNWRE-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-fluoro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(F)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 XVLQJDCWMUNWRE-UHFFFAOYSA-N 0.000 claims description 17
TZLPVLNZOJKCEX-UHFFFAOYSA-N 2-[5-chloro-2-(3-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(Cl)=C1 TZLPVLNZOJKCEX-UHFFFAOYSA-N 0.000 claims description 17
MLZIULVXMJPQQB-UHFFFAOYSA-N 2-[5-chloro-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 MLZIULVXMJPQQB-UHFFFAOYSA-N 0.000 claims description 17
SVWRECMQWQPKMV-UHFFFAOYSA-N 2-[5-chloro-2-(4-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC(Cl)=CC=N1 SVWRECMQWQPKMV-UHFFFAOYSA-N 0.000 claims description 17
NBWDQAZRDWYIEX-UHFFFAOYSA-N 2-[5-chloro-2-(4-ethyl-3-fluoropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1F NBWDQAZRDWYIEX-UHFFFAOYSA-N 0.000 claims description 17
VZEKGVPKLLSTGW-UHFFFAOYSA-N 2-[5-chloro-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 VZEKGVPKLLSTGW-UHFFFAOYSA-N 0.000 claims description 17
FHPMEIVAUMQJDE-UHFFFAOYSA-N 2-[5-chloro-2-(4-methoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 FHPMEIVAUMQJDE-UHFFFAOYSA-N 0.000 claims description 17
RLFOJZHXUDIGJS-UHFFFAOYSA-N 2-[5-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 RLFOJZHXUDIGJS-UHFFFAOYSA-N 0.000 claims description 17
DNIKRHXQZCTYOD-UHFFFAOYSA-N 2-[5-fluoro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(F)=CC=C3N2)CC(O)=O)=C1 DNIKRHXQZCTYOD-UHFFFAOYSA-N 0.000 claims description 17
BDNUVQMJHCYXNX-UHFFFAOYSA-N 2-[6-chloro-2-(3-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(Cl)=C1 BDNUVQMJHCYXNX-UHFFFAOYSA-N 0.000 claims description 17
YDQDBRSFDWZTGQ-UHFFFAOYSA-N 2-[6-chloro-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 YDQDBRSFDWZTGQ-UHFFFAOYSA-N 0.000 claims description 17
LUGZWOKPMJPQCG-UHFFFAOYSA-N 2-[6-chloro-2-(4-chlorobenzoyl)-5-fluoro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=C(F)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 LUGZWOKPMJPQCG-UHFFFAOYSA-N 0.000 claims description 17
DIPIROZSUXXMDC-UHFFFAOYSA-N 2-[6-chloro-2-(4-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC(Cl)=CC=N1 DIPIROZSUXXMDC-UHFFFAOYSA-N 0.000 claims description 17
CBOZTEXMHUCFHN-UHFFFAOYSA-N 2-[6-chloro-2-(4-ethyl-3-fluoropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1F CBOZTEXMHUCFHN-UHFFFAOYSA-N 0.000 claims description 17
RGLFGUMIFBYKFQ-UHFFFAOYSA-N 2-[6-chloro-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 RGLFGUMIFBYKFQ-UHFFFAOYSA-N 0.000 claims description 17
ABXKVHVCGDJWJE-UHFFFAOYSA-N 2-[6-chloro-2-(4-methoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 ABXKVHVCGDJWJE-UHFFFAOYSA-N 0.000 claims description 17
RFUDIMXRYHINIU-UHFFFAOYSA-N 2-[6-chloro-2-(4-methoxypyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 RFUDIMXRYHINIU-UHFFFAOYSA-N 0.000 claims description 17
BPOHSYQWAARKKL-UHFFFAOYSA-N 2-[6-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 BPOHSYQWAARKKL-UHFFFAOYSA-N 0.000 claims description 17
VCBDDETUJPLUQF-UHFFFAOYSA-N 2-[6-chloro-2-(4-propan-2-ylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC(C)C1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 VCBDDETUJPLUQF-UHFFFAOYSA-N 0.000 claims description 17
NIVOIXNJFYAHEY-UHFFFAOYSA-N 2-[6-chloro-2-(4-propylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 NIVOIXNJFYAHEY-UHFFFAOYSA-N 0.000 claims description 17
CYAAZZVFMHQIDN-UHFFFAOYSA-N 2-[6-chloro-2-(5-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1=CC(C)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 CYAAZZVFMHQIDN-UHFFFAOYSA-N 0.000 claims description 17
ONMIXEWCFUIZSY-UHFFFAOYSA-N 2-[6-chloro-2-(isoquinoline-3-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC=C2C=NC(C(=O)C3=C(C4=CC=C(Cl)C=C4N3)CC(=O)O)=CC2=C1 ONMIXEWCFUIZSY-UHFFFAOYSA-N 0.000 claims description 17
UEMRRUGDDLKXAI-UHFFFAOYSA-N 2-[6-chloro-2-(pyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=N1 UEMRRUGDDLKXAI-UHFFFAOYSA-N 0.000 claims description 17
YESINYJNRVODPJ-UHFFFAOYSA-N 2-[6-methyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC=C(C)C=C3N2)CC(O)=O)=C1 YESINYJNRVODPJ-UHFFFAOYSA-N 0.000 claims description 17
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 17
AIMJTNLASDKXRX-UHFFFAOYSA-N 2-[2-(4-ethylpyridine-2-carbonyl)-5-(trifluoromethyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(=CC=C3N2)C(F)(F)F)CC(O)=O)=C1 AIMJTNLASDKXRX-UHFFFAOYSA-N 0.000 claims description 16
OVWLTNXNSZARCP-UHFFFAOYSA-N 2-[5-chloro-2-(isoquinoline-3-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC=C2C=NC(C(=O)C3=C(C4=CC(Cl)=CC=C4N3)CC(=O)O)=CC2=C1 OVWLTNXNSZARCP-UHFFFAOYSA-N 0.000 claims description 16
LROJUDNAHMMTRQ-UHFFFAOYSA-N 2-[6-chloro-2-(1-methylimidazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CN1C=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 LROJUDNAHMMTRQ-UHFFFAOYSA-N 0.000 claims description 16
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
239000011698 potassium fluoride Substances 0.000 claims description 15
235000003270 potassium fluoride Nutrition 0.000 claims description 15
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
WZVXGBZLTRACHK-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(Cl)=CC=N1 WZVXGBZLTRACHK-UHFFFAOYSA-N 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 14
229910052708 sodium Inorganic materials 0.000 claims description 14
WQWCZMUDOGVFDT-UHFFFAOYSA-N 2-[6-chloro-2-[4-(1-hydroxyethyl)pyridine-2-carbonyl]-1h-indol-3-yl]acetic acid Chemical compound CC(O)C1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 WQWCZMUDOGVFDT-UHFFFAOYSA-N 0.000 claims description 13
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
125000004076 pyridyl group Chemical group 0.000 claims description 13
239000011734 sodium Chemical class 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
ZDJRFRQLCMSGPP-UHFFFAOYSA-N 2-[2-(3-bromobenzoyl)-6-chloro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(Br)=C1 ZDJRFRQLCMSGPP-UHFFFAOYSA-N 0.000 claims description 12
QFIPOAGESQAQMM-UHFFFAOYSA-N 2-[2-(3-chlorobenzoyl)-5-fluoro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(F)C=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(Cl)=C1 QFIPOAGESQAQMM-UHFFFAOYSA-N 0.000 claims description 12
MUNCFAXGBGQJGQ-UHFFFAOYSA-N 2-[2-(4-bromobenzoyl)-6-chloro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Br)C=C1 MUNCFAXGBGQJGQ-UHFFFAOYSA-N 0.000 claims description 12
MXYBRVWAGAYMRD-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-(trifluoromethyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(C(F)(F)F)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 MXYBRVWAGAYMRD-UHFFFAOYSA-N 0.000 claims description 12
UVHKKXATRFCHKH-UHFFFAOYSA-N 2-[2-(4-methylpyridine-2-carbonyl)-5-(trifluoromethyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(=CC=C3N2)C(F)(F)F)CC(O)=O)=C1 UVHKKXATRFCHKH-UHFFFAOYSA-N 0.000 claims description 12
ZZJAAJNNPOFPLR-UHFFFAOYSA-N 2-[2-(4-methylpyridine-2-carbonyl)-5-propan-2-yl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(C(C)C)=CC=C2NC=1C(=O)C1=CC(C)=CC=N1 ZZJAAJNNPOFPLR-UHFFFAOYSA-N 0.000 claims description 12
BCWXTKUXLJZSTK-UHFFFAOYSA-N 2-[2-(4-methylpyridine-2-carbonyl)-6-(trifluoromethyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC=C(C=C3N2)C(F)(F)F)CC(O)=O)=C1 BCWXTKUXLJZSTK-UHFFFAOYSA-N 0.000 claims description 12
SDAHUFUEJMCQRJ-UHFFFAOYSA-N 2-[5-chloro-2-(1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=NC=CS1 SDAHUFUEJMCQRJ-UHFFFAOYSA-N 0.000 claims description 12
MQSROOYLIQDQPL-UHFFFAOYSA-N 2-[5-chloro-2-(2-methyl-1h-imidazole-5-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C(C)=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 MQSROOYLIQDQPL-UHFFFAOYSA-N 0.000 claims description 12
GTTDZFUQPRBOIU-UHFFFAOYSA-N 2-[5-chloro-2-(3-methylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 GTTDZFUQPRBOIU-UHFFFAOYSA-N 0.000 claims description 12
LDAHATKHGBUGKA-UHFFFAOYSA-N 2-[5-chloro-2-(4,5-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound C1=C(C)C(C)=CN=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 LDAHATKHGBUGKA-UHFFFAOYSA-N 0.000 claims description 12
RQLXLOPZXVMJFH-UHFFFAOYSA-N 2-[5-chloro-2-(5-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=N1 RQLXLOPZXVMJFH-UHFFFAOYSA-N 0.000 claims description 12
QYHVJTBMBTUHLF-UHFFFAOYSA-N 2-[5-chloro-2-(6-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=N1 QYHVJTBMBTUHLF-UHFFFAOYSA-N 0.000 claims description 12
RBDFSQQYFRTJJZ-UHFFFAOYSA-N 2-[5-chloro-2-[4-(trifluoromethoxy)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(OC(F)(F)F)C=C1 RBDFSQQYFRTJJZ-UHFFFAOYSA-N 0.000 claims description 12
FTJUWQKJMWEILQ-UHFFFAOYSA-N 2-[5-ethyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(CC)=CC=C2NC=1C(=O)C1=CC(C)=CC=N1 FTJUWQKJMWEILQ-UHFFFAOYSA-N 0.000 claims description 12
PWSNKQDYXDTFKA-UHFFFAOYSA-N 2-[5-tert-butyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(=CC=C3N2)C(C)(C)C)CC(O)=O)=C1 PWSNKQDYXDTFKA-UHFFFAOYSA-N 0.000 claims description 12
MRLKUSHNICBCJA-UHFFFAOYSA-N 2-[6-chloro-2-(3-chloro-4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1Cl MRLKUSHNICBCJA-UHFFFAOYSA-N 0.000 claims description 12
XOKAZAIZAKWWKK-UHFFFAOYSA-N 2-[6-chloro-2-(3-ethoxy-4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCOC1=C(CC)C=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 XOKAZAIZAKWWKK-UHFFFAOYSA-N 0.000 claims description 12
OECDPNLTRYRKMK-UHFFFAOYSA-N 2-[6-chloro-2-(3-fluorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(F)=C1 OECDPNLTRYRKMK-UHFFFAOYSA-N 0.000 claims description 12
VEMVFTJSNATNQV-UHFFFAOYSA-N 2-[6-chloro-2-(4-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CSC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=N1 VEMVFTJSNATNQV-UHFFFAOYSA-N 0.000 claims description 12
NFJIBUCJDVLYSZ-UHFFFAOYSA-N 2-[6-chloro-2-(4-methylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC(C)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 NFJIBUCJDVLYSZ-UHFFFAOYSA-N 0.000 claims description 12
ZNNURDZEITVFDY-UHFFFAOYSA-N 2-[6-chloro-2-(5-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound S1C(C)=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 ZNNURDZEITVFDY-UHFFFAOYSA-N 0.000 claims description 12
CDPAPELXWJAQSY-UHFFFAOYSA-N 2-[6-chloro-2-(6-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=N1 CDPAPELXWJAQSY-UHFFFAOYSA-N 0.000 claims description 12
FEZIMDVJVWMTGO-UHFFFAOYSA-N 2-[6-chloro-2-(cyclohexanecarbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1CCCCC1 FEZIMDVJVWMTGO-UHFFFAOYSA-N 0.000 claims description 12
PCOWMZVUUCRSQV-UHFFFAOYSA-N 2-[6-chloro-2-[3-(methoxymethyl)furan-2-carbonyl]-1h-indol-3-yl]acetic acid Chemical compound C1=COC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1COC PCOWMZVUUCRSQV-UHFFFAOYSA-N 0.000 claims description 12
SGDBQSCWSGKGKR-UHFFFAOYSA-N 2-[6-chloro-2-[4-(trifluoromethoxy)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(OC(F)(F)F)C=C1 SGDBQSCWSGKGKR-UHFFFAOYSA-N 0.000 claims description 12
DSUAFFATXOUZKH-UHFFFAOYSA-N 2-[6-chloro-2-[4-(trifluoromethyl)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(C(F)(F)F)C=C1 DSUAFFATXOUZKH-UHFFFAOYSA-N 0.000 claims description 12
125000002541 furyl group Chemical group 0.000 claims description 12
VJIDCNNMSCMLIP-UHFFFAOYSA-N methyl 2-(2-benzoyl-6-chloro-1h-indol-3-yl)acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC=C1 VJIDCNNMSCMLIP-UHFFFAOYSA-N 0.000 claims description 12
RDCTWILJYCSIGQ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=CS1 RDCTWILJYCSIGQ-UHFFFAOYSA-N 0.000 claims description 12
OTLKTDXZJMGTRZ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(6-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC(C)=N1 OTLKTDXZJMGTRZ-UHFFFAOYSA-N 0.000 claims description 12
ZEQZTKODWNBFBB-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C=C1 ZEQZTKODWNBFBB-UHFFFAOYSA-N 0.000 claims description 12
ZFKCRNCLYPCFID-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(=O)OC)=C1 ZFKCRNCLYPCFID-UHFFFAOYSA-N 0.000 claims description 12
UCERSLPTIOPWFC-UHFFFAOYSA-N methyl 2-[6-chloro-2-[4-(1-hydroxyethyl)pyridine-2-carbonyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(C(C)O)=CC=N1 UCERSLPTIOPWFC-UHFFFAOYSA-N 0.000 claims description 12
239000011736 potassium bicarbonate Substances 0.000 claims description 12
235000015497 potassium bicarbonate Nutrition 0.000 claims description 12
229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 12
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 12
229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
QRPCOTHMNUSSAE-UHFFFAOYSA-N 2-[5-chloro-2-(4-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CSC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=N1 QRPCOTHMNUSSAE-UHFFFAOYSA-N 0.000 claims description 11
SPAHFOWWQPUGOE-UHFFFAOYSA-N 2-[5-chloro-2-(5-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1=CC(C)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 SPAHFOWWQPUGOE-UHFFFAOYSA-N 0.000 claims description 11
ZXIRTFSPGPHKHH-UHFFFAOYSA-N 2-[5-methyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(C)=CC=C3N2)CC(O)=O)=C1 ZXIRTFSPGPHKHH-UHFFFAOYSA-N 0.000 claims description 11
JSHSAONBVOGQCR-UHFFFAOYSA-N 2-[6-chloro-2-(4,5-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound C1=C(C)C(C)=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 JSHSAONBVOGQCR-UHFFFAOYSA-N 0.000 claims description 11
OBOGPOWHCAHBJA-UHFFFAOYSA-N 2-[6-chloro-2-(4-fluorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(F)C=C1 OBOGPOWHCAHBJA-UHFFFAOYSA-N 0.000 claims description 11
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 11
125000005956 isoquinolyl group Chemical group 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
125000000168 pyrrolyl group Chemical group 0.000 claims description 11
235000011121 sodium hydroxide Nutrition 0.000 claims description 11
125000000335 thiazolyl group Chemical group 0.000 claims description 11
125000001544 thienyl group Chemical group 0.000 claims description 11
IDIWDXHXQKDYOH-UHFFFAOYSA-N 2-[5-chloro-2-(5-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound S1C(C)=CN=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 IDIWDXHXQKDYOH-UHFFFAOYSA-N 0.000 claims description 10
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
VQLKXSHAOFDVGU-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-methyl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(C)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 VQLKXSHAOFDVGU-UHFFFAOYSA-N 0.000 claims description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 9
239000007864 aqueous solution Substances 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 9
125000002883 imidazolyl group Chemical group 0.000 claims description 9
125000000842 isoxazolyl group Chemical group 0.000 claims description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
239000012312 sodium hydride Substances 0.000 claims description 9
229910000104 sodium hydride Inorganic materials 0.000 claims description 9
SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims description 8
CTWYRHDFWKRRKA-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-(trifluoromethoxy)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(OC(F)(F)F)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 CTWYRHDFWKRRKA-UHFFFAOYSA-N 0.000 claims description 8
IIWDFIMVYFBIKL-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-6-methyl-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(C)=CC=C2C(CC(O)=O)=C1C(=O)C1=CC=C(Cl)C=C1 IIWDFIMVYFBIKL-UHFFFAOYSA-N 0.000 claims description 8
DHIDFWSDRQOSCX-UHFFFAOYSA-N 2-[2-(4-tert-butylpyridine-2-carbonyl)-6-chloro-1h-indol-3-yl]acetic acid Chemical compound CC(C)(C)C1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 DHIDFWSDRQOSCX-UHFFFAOYSA-N 0.000 claims description 8
MEAGKTRNERIYOR-UHFFFAOYSA-N 2-[5-chloro-2-(3-chloro-4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1Cl MEAGKTRNERIYOR-UHFFFAOYSA-N 0.000 claims description 8
LIEWVLGYSUZMPB-UHFFFAOYSA-N 2-[5-chloro-2-(4-methoxypyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 LIEWVLGYSUZMPB-UHFFFAOYSA-N 0.000 claims description 8
QJAKXUJCEPEDLE-UHFFFAOYSA-N 2-[5-chloro-2-(4-propylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 QJAKXUJCEPEDLE-UHFFFAOYSA-N 0.000 claims description 8
RMXKBFBIJOCEEU-UHFFFAOYSA-N 2-[5-ethyl-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(CC)=CC=C3N2)CC(O)=O)=C1 RMXKBFBIJOCEEU-UHFFFAOYSA-N 0.000 claims description 8
UOCATRDNSWBSKC-UHFFFAOYSA-N 2-[6-chloro-2-(3,5-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC(C)=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 UOCATRDNSWBSKC-UHFFFAOYSA-N 0.000 claims description 8
FKVFYNCOVBCCRI-UHFFFAOYSA-N 2-[6-chloro-2-(3-methylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 FKVFYNCOVBCCRI-UHFFFAOYSA-N 0.000 claims description 8
JIRSXUHWEMMDHG-UHFFFAOYSA-N 2-[6-chloro-2-(3-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CN=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 JIRSXUHWEMMDHG-UHFFFAOYSA-N 0.000 claims description 8
YERXLEPFLRGTEC-UHFFFAOYSA-N 2-[6-chloro-2-(furan-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CO1 YERXLEPFLRGTEC-UHFFFAOYSA-N 0.000 claims description 8
CDQGPNGXWXAMTJ-UHFFFAOYSA-N 2-[6-chloro-2-[3-(trifluoromethyl)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(C(F)(F)F)=C1 CDQGPNGXWXAMTJ-UHFFFAOYSA-N 0.000 claims description 8
XXXVGINRZSHYHM-UHFFFAOYSA-N 2-[6-chloro-5-fluoro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(F)=C(Cl)C=C3N2)CC(O)=O)=C1 XXXVGINRZSHYHM-UHFFFAOYSA-N 0.000 claims description 8
PUNPGZCYHPEVOI-UHFFFAOYSA-N 2-[6-ethyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(CC)=CC=C2C(CC(O)=O)=C1C(=O)C1=CC(C)=CC=N1 PUNPGZCYHPEVOI-UHFFFAOYSA-N 0.000 claims description 8
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 8
AKBZGRBYTSHPNP-UHFFFAOYSA-N ethyl 2-(2-benzoyl-6-chloro-1h-indol-3-yl)acetate Chemical class N1C2=CC(Cl)=CC=C2C(CC(=O)OCC)=C1C(=O)C1=CC=CC=C1 AKBZGRBYTSHPNP-UHFFFAOYSA-N 0.000 claims description 8
125000001153 fluoro group Chemical group F* 0.000 claims description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
QMTMMRYOKQOECS-UHFFFAOYSA-N methyl 2-[2-(4-ethylpyridine-2-carbonyl)-5-(trifluoromethyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(=CC=C3N2)C(F)(F)F)CC(=O)OC)=C1 QMTMMRYOKQOECS-UHFFFAOYSA-N 0.000 claims description 8
TUIXRWUNIYZKSM-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(Cl)=CC=N1 TUIXRWUNIYZKSM-UHFFFAOYSA-N 0.000 claims description 8
LQIXBCDBBLTNSJ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-ethyl-3-fluoropyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)OC)=C1F LQIXBCDBBLTNSJ-UHFFFAOYSA-N 0.000 claims description 8
CKEARHMPPKSQCH-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)OC)=C1 CKEARHMPPKSQCH-UHFFFAOYSA-N 0.000 claims description 8
YYONNDLDBWXJTE-UHFFFAOYSA-N methyl 2-[5-chloro-2-(5-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=C(C)S1 YYONNDLDBWXJTE-UHFFFAOYSA-N 0.000 claims description 8
GVJWORSWXAADOI-UHFFFAOYSA-N methyl 2-[5-chloro-2-(isoquinoline-3-carbonyl)-1h-indol-3-yl]acetate Chemical compound C1=CC=C2C=NC(C(=O)C3=C(C4=CC(Cl)=CC=C4N3)CC(=O)OC)=CC2=C1 GVJWORSWXAADOI-UHFFFAOYSA-N 0.000 claims description 8
AWEROMAJRHRVJO-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-methoxypyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(OC)=CC=N1 AWEROMAJRHRVJO-UHFFFAOYSA-N 0.000 claims description 8
HHVBWFNLRLXCNX-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-propan-2-ylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(C(C)C)=CC=N1 HHVBWFNLRLXCNX-UHFFFAOYSA-N 0.000 claims description 8
GHWDSYRPKXPDOE-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-propylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(=O)OC)=C1 GHWDSYRPKXPDOE-UHFFFAOYSA-N 0.000 claims description 8
LIFOJSQXTVEAAX-UHFFFAOYSA-N methyl 2-[6-chloro-2-(5-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C=N1 LIFOJSQXTVEAAX-UHFFFAOYSA-N 0.000 claims description 8
PIXVHIRVGBWQHI-UHFFFAOYSA-N methyl 2-[6-chloro-2-(isoquinoline-3-carbonyl)-1h-indol-3-yl]acetate Chemical compound C1=CC=C2C=NC(C(=O)C3=C(C4=CC=C(Cl)C=C4N3)CC(=O)OC)=CC2=C1 PIXVHIRVGBWQHI-UHFFFAOYSA-N 0.000 claims description 8
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 8
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
SCECXPYERIUNDX-UHFFFAOYSA-N 2-[5-methoxy-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(OC)=CC=C2NC=1C(=O)C1=CC(C)=CC=N1 SCECXPYERIUNDX-UHFFFAOYSA-N 0.000 claims description 7
ABLJUXJPXHNJRV-UHFFFAOYSA-N 2-[6-chloro-2-(3-methoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=CC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 ABLJUXJPXHNJRV-UHFFFAOYSA-N 0.000 claims description 7
BVLDTQOJHAZUMB-UHFFFAOYSA-N 2-[6-methoxy-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(OC)=CC=C2C(CC(O)=O)=C1C(=O)C1=CC(C)=CC=N1 BVLDTQOJHAZUMB-UHFFFAOYSA-N 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
229940043279 diisopropylamine Drugs 0.000 claims description 7
ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 claims description 7
LIZBZHRWLFNNNY-UHFFFAOYSA-N 2-[6-chloro-2-(4,6-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC(C)=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 LIZBZHRWLFNNNY-UHFFFAOYSA-N 0.000 claims description 6
YVHSHSNTRIAXKH-UHFFFAOYSA-N 2-[6-chloro-2-(5-methyl-1,2-oxazole-3-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound O1C(C)=CC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=N1 YVHSHSNTRIAXKH-UHFFFAOYSA-N 0.000 claims description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 6
125000001041 indolyl group Chemical group 0.000 claims description 6
GRKFHJQVUZJDLR-UHFFFAOYSA-N methyl 2-[2-(4-methylpyridine-2-carbonyl)-5-(trifluoromethoxy)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(OC(F)(F)F)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC=N1 GRKFHJQVUZJDLR-UHFFFAOYSA-N 0.000 claims description 6
ZTBBQMAVBBNDSU-UHFFFAOYSA-N methyl 2-[5,6-dichloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC=N1 ZTBBQMAVBBNDSU-UHFFFAOYSA-N 0.000 claims description 6
KMWIDMYXNFISRM-UHFFFAOYSA-N methyl 2-[5-chloro-2-(2-methyl-1h-imidazole-5-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CNC(C)=N1 KMWIDMYXNFISRM-UHFFFAOYSA-N 0.000 claims description 6
ONWHWGCLUPWJEL-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4,5-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=C(C)C=N1 ONWHWGCLUPWJEL-UHFFFAOYSA-N 0.000 claims description 6
NGQCMODJGDZYPG-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4,6-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC(C)=N1 NGQCMODJGDZYPG-UHFFFAOYSA-N 0.000 claims description 6
SRIAHUPVRCEVHA-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC(C)=CS1 SRIAHUPVRCEVHA-UHFFFAOYSA-N 0.000 claims description 6
WANHWOGHEHZADH-UHFFFAOYSA-N methyl 2-[5-chloro-2-(5-chloropyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C=N1 WANHWOGHEHZADH-UHFFFAOYSA-N 0.000 claims description 6
YDBSPIZAPVSXBP-UHFFFAOYSA-N methyl 2-[5-chloro-2-(5-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(C)C=N1 YDBSPIZAPVSXBP-UHFFFAOYSA-N 0.000 claims description 6
HVECEOGUMBIZGR-UHFFFAOYSA-N methyl 2-[5-chloro-2-[4-(trifluoromethoxy)benzoyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(OC(F)(F)F)C=C1 HVECEOGUMBIZGR-UHFFFAOYSA-N 0.000 claims description 6
HUVVRRBFGIXOAA-UHFFFAOYSA-N methyl 2-[5-ethyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound COC(=O)CC=1C2=CC(CC)=CC=C2NC=1C(=O)C1=CC(C)=CC=N1 HUVVRRBFGIXOAA-UHFFFAOYSA-N 0.000 claims description 6
CEXBEBSAIJGUBG-UHFFFAOYSA-N methyl 2-[5-tert-butyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(C(C)(C)C)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC=N1 CEXBEBSAIJGUBG-UHFFFAOYSA-N 0.000 claims description 6
UEZFVZGSGFGLIF-UHFFFAOYSA-N methyl 2-[6-chloro-2-(3-chloro-4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(=O)OC)=C1Cl UEZFVZGSGFGLIF-UHFFFAOYSA-N 0.000 claims description 6
NMTHUPOCGNUMEK-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=NC(C)=CS1 NMTHUPOCGNUMEK-UHFFFAOYSA-N 0.000 claims description 6
XYQZXDXEEPSBPJ-UHFFFAOYSA-N methyl 2-[6-chloro-2-(5-methyl-1,3-thiazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=NC=C(C)S1 XYQZXDXEEPSBPJ-UHFFFAOYSA-N 0.000 claims description 6
LNIJCVFQXWXLKY-UHFFFAOYSA-N methyl 2-[6-chloro-2-(6-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC(C)=N1 LNIJCVFQXWXLKY-UHFFFAOYSA-N 0.000 claims description 6
IRBMLUJBILFHQT-UHFFFAOYSA-N methyl 2-[6-chloro-2-[3-(methoxymethyl)furan-2-carbonyl]-1h-indol-3-yl]acetate Chemical compound C1=COC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(=O)OC)=C1COC IRBMLUJBILFHQT-UHFFFAOYSA-N 0.000 claims description 6
LIUFUQWEKBCFTN-UHFFFAOYSA-N methyl 2-[6-chloro-2-[4-(trifluoromethoxy)benzoyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(OC(F)(F)F)C=C1 LIUFUQWEKBCFTN-UHFFFAOYSA-N 0.000 claims description 6
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 6
229910000105 potassium hydride Inorganic materials 0.000 claims description 6
235000011118 potassium hydroxide Nutrition 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 6
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 6
125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
125000002971 oxazolyl group Chemical group 0.000 claims description 5
125000003373 pyrazinyl group Chemical group 0.000 claims description 5
125000002098 pyridazinyl group Chemical group 0.000 claims description 5
125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
125000005493 quinolyl group Chemical group 0.000 claims description 5
125000003831 tetrazolyl group Chemical group 0.000 claims description 5
125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
125000001425 triazolyl group Chemical group 0.000 claims description 5
SSUJUUNLZQVZMO-UHFFFAOYSA-N 1,2,3,4,8,9,10,10a-octahydropyrimido[1,2-a]azepine Chemical group C1CCC=CN2CCCNC21 SSUJUUNLZQVZMO-UHFFFAOYSA-N 0.000 claims description 4
GJLNHTUJBBNDLC-UHFFFAOYSA-N 2-(2-benzoyl-1h-indol-3-yl)acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 GJLNHTUJBBNDLC-UHFFFAOYSA-N 0.000 claims description 4
KEJUQGPSVNKHSC-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)propanoic acid Chemical compound N1C2=CC(Cl)=CC=C2C(C(C(O)=O)C)=C1C(=O)C1=CC=CC=C1 KEJUQGPSVNKHSC-UHFFFAOYSA-N 0.000 claims description 4
REPIIDDWHHDMRS-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 REPIIDDWHHDMRS-UHFFFAOYSA-N 0.000 claims description 4
AGVMPGOZKHQYKZ-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-methoxy-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(OC)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 AGVMPGOZKHQYKZ-UHFFFAOYSA-N 0.000 claims description 4
DWCCDPOQTMLZAY-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-propan-2-yl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(C(C)C)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 DWCCDPOQTMLZAY-UHFFFAOYSA-N 0.000 claims description 4
HXTHBFZIZKGEHC-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-6-methoxy-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(OC)=CC=C2C(CC(O)=O)=C1C(=O)C1=CC=C(Cl)C=C1 HXTHBFZIZKGEHC-UHFFFAOYSA-N 0.000 claims description 4
JXSPPEWQPDAQFQ-UHFFFAOYSA-N 2-[2-(4-ethylpyridine-2-carbonyl)-5-(trifluoromethoxy)-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(OC(F)(F)F)=CC=C3N2)CC(O)=O)=C1 JXSPPEWQPDAQFQ-UHFFFAOYSA-N 0.000 claims description 4
ZMUGLKQRLOVWJZ-UHFFFAOYSA-N 2-[2-(4-methylpyridine-2-carbonyl)-5-methylsulfanyl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(SC)=CC=C2NC=1C(=O)C1=CC(C)=CC=N1 ZMUGLKQRLOVWJZ-UHFFFAOYSA-N 0.000 claims description 4
LGKDKGPYTHYCKN-UHFFFAOYSA-N 2-[2-(4-tert-butylpyridine-2-carbonyl)-5-chloro-1h-indol-3-yl]acetic acid Chemical compound CC(C)(C)C1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 LGKDKGPYTHYCKN-UHFFFAOYSA-N 0.000 claims description 4
SMENJXNEXWHJSS-UHFFFAOYSA-N 2-[5-acetyl-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(C(=O)C)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 SMENJXNEXWHJSS-UHFFFAOYSA-N 0.000 claims description 4
ABTBSQFGUWMFGT-UHFFFAOYSA-N 2-[5-chloro-2-(1,3-thiazole-5-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CN=CS1 ABTBSQFGUWMFGT-UHFFFAOYSA-N 0.000 claims description 4
OULUBRHRDAHLSZ-UHFFFAOYSA-N 2-[5-chloro-2-(1-methylimidazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CN1C=CN=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 OULUBRHRDAHLSZ-UHFFFAOYSA-N 0.000 claims description 4
IQDVZLRPPBNUQI-UHFFFAOYSA-N 2-[5-chloro-2-(1-methylpyrrole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CN1C=CC=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 IQDVZLRPPBNUQI-UHFFFAOYSA-N 0.000 claims description 4
RBOPJCFKQFIKPV-UHFFFAOYSA-N 2-[5-chloro-2-(1h-imidazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=NC=CN1 RBOPJCFKQFIKPV-UHFFFAOYSA-N 0.000 claims description 4
GMYIEFGNSRBNET-UHFFFAOYSA-N 2-[5-chloro-2-(3,4-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1C GMYIEFGNSRBNET-UHFFFAOYSA-N 0.000 claims description 4
IVAUGGRLHAAOFW-UHFFFAOYSA-N 2-[5-chloro-2-(3-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CN=C1C(=O)C1=C(CC(O)=O)C2=CC(Cl)=CC=C2N1 IVAUGGRLHAAOFW-UHFFFAOYSA-N 0.000 claims description 4
XHQGSUNBBZGFRK-UHFFFAOYSA-N 2-[5-chloro-2-(4-methylthiadiazole-5-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1=NSC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1C XHQGSUNBBZGFRK-UHFFFAOYSA-N 0.000 claims description 4
CEXUHYCXEAOFGH-UHFFFAOYSA-N 2-[5-chloro-2-(4-propan-2-ylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC(C)C1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 CEXUHYCXEAOFGH-UHFFFAOYSA-N 0.000 claims description 4
IBOLAADZZHVSAR-UHFFFAOYSA-N 2-[5-methoxy-2-(3-methylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(OC)=CC=C2NC=1C(=O)C1=CC=CC(C)=C1 IBOLAADZZHVSAR-UHFFFAOYSA-N 0.000 claims description 4
HWEGSYUCJYLKEO-UHFFFAOYSA-N 2-[5-tert-butyl-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(C(C)(C)C)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 HWEGSYUCJYLKEO-UHFFFAOYSA-N 0.000 claims description 4
QAMOOWGWIKTUMJ-UHFFFAOYSA-N 2-[6-chloro-2-(1h-imidazole-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=NC=CN1 QAMOOWGWIKTUMJ-UHFFFAOYSA-N 0.000 claims description 4
KFKUCBZEFWIDMF-UHFFFAOYSA-N 2-[6-chloro-2-(2,4-dichlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1Cl KFKUCBZEFWIDMF-UHFFFAOYSA-N 0.000 claims description 4
XHHKFYKUQVEIBW-UHFFFAOYSA-N 2-[6-chloro-2-(2,4-dimethoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 XHHKFYKUQVEIBW-UHFFFAOYSA-N 0.000 claims description 4
UGWKNVNCTSOSPC-UHFFFAOYSA-N 2-[6-chloro-2-(2,5-dimethoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=C(OC)C(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1 UGWKNVNCTSOSPC-UHFFFAOYSA-N 0.000 claims description 4
WQLYUKKMPCQWHO-UHFFFAOYSA-N 2-[6-chloro-2-(2-chlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1Cl WQLYUKKMPCQWHO-UHFFFAOYSA-N 0.000 claims description 4
RDZSLOZUFJIMIQ-UHFFFAOYSA-N 2-[6-chloro-2-(2-methoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 RDZSLOZUFJIMIQ-UHFFFAOYSA-N 0.000 claims description 4
UTFYAEXHTQANTC-UHFFFAOYSA-N 2-[6-chloro-2-(2-methylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 UTFYAEXHTQANTC-UHFFFAOYSA-N 0.000 claims description 4
CTPVZFGXLCCGCB-UHFFFAOYSA-N 2-[6-chloro-2-(2-nitrobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1[N+]([O-])=O CTPVZFGXLCCGCB-UHFFFAOYSA-N 0.000 claims description 4
CYYVGLKURAVGDF-UHFFFAOYSA-N 2-[6-chloro-2-(3,4-dichlorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C(Cl)=C1 CYYVGLKURAVGDF-UHFFFAOYSA-N 0.000 claims description 4
KLMKJYYUYYUXHX-UHFFFAOYSA-N 2-[6-chloro-2-(3-hydroxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC(O)=C1 KLMKJYYUYYUXHX-UHFFFAOYSA-N 0.000 claims description 4
BTJFKTMURWZAJV-UHFFFAOYSA-N 2-[6-chloro-2-(3-phenylmethoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 BTJFKTMURWZAJV-UHFFFAOYSA-N 0.000 claims description 4
AHFMJVAAHUQZDC-UHFFFAOYSA-N 2-[6-chloro-2-(4-chloro-3-fluorobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C(F)=C1 AHFMJVAAHUQZDC-UHFFFAOYSA-N 0.000 claims description 4
RDMSEDZQZOMHRP-UHFFFAOYSA-N 2-[6-chloro-2-(4-hydroxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(O)C=C1 RDMSEDZQZOMHRP-UHFFFAOYSA-N 0.000 claims description 4
YOQMNEYHUVOVPY-UHFFFAOYSA-N 2-[6-chloro-2-(4-methylthiadiazole-5-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1=NSC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1C YOQMNEYHUVOVPY-UHFFFAOYSA-N 0.000 claims description 4
OSKCEEYCWRBVKE-UHFFFAOYSA-N 2-[6-chloro-2-(4-nitrobenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C([N+]([O-])=O)C=C1 OSKCEEYCWRBVKE-UHFFFAOYSA-N 0.000 claims description 4
LCSYYVIRAZLJEZ-UHFFFAOYSA-N 2-[6-chloro-2-(4-phenylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 LCSYYVIRAZLJEZ-UHFFFAOYSA-N 0.000 claims description 4
XDVJPEGYXRZAHA-UHFFFAOYSA-N 2-[6-chloro-2-(4-phenylmethoxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 XDVJPEGYXRZAHA-UHFFFAOYSA-N 0.000 claims description 4
ATFMTASOJDFHRU-UHFFFAOYSA-N 2-[6-chloro-2-(4-propan-2-yloxybenzoyl)-1h-indol-3-yl]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)C1=C(CC(O)=O)C2=CC=C(Cl)C=C2N1 ATFMTASOJDFHRU-UHFFFAOYSA-N 0.000 claims description 4
UUTBCXFMIZSDOV-UHFFFAOYSA-N 2-[6-chloro-2-(cyclobutanecarbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1CCC1 UUTBCXFMIZSDOV-UHFFFAOYSA-N 0.000 claims description 4
OIBLRFJTXXDCRU-UHFFFAOYSA-N 2-[6-chloro-2-(cyclopropanecarbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1CC1 OIBLRFJTXXDCRU-UHFFFAOYSA-N 0.000 claims description 4
JRNYJEFZKAFDOI-UHFFFAOYSA-N 2-[6-chloro-2-(pyridine-4-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=NC=C1 JRNYJEFZKAFDOI-UHFFFAOYSA-N 0.000 claims description 4
SPBSENZPLJNKIP-UHFFFAOYSA-N 2-[6-chloro-2-(thiophene-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CS1 SPBSENZPLJNKIP-UHFFFAOYSA-N 0.000 claims description 4
JBFKNMAMZZPTLN-UHFFFAOYSA-N 2-[6-chloro-2-[3-(2-hydroxypropan-2-yl)furan-2-carbonyl]-1h-indol-3-yl]acetic acid Chemical compound C1=COC(C(=O)C2=C(C3=CC=C(Cl)C=C3N2)CC(O)=O)=C1C(C)(O)C JBFKNMAMZZPTLN-UHFFFAOYSA-N 0.000 claims description 4
TUGJBGFXDURIOG-UHFFFAOYSA-N 2-[6-chloro-2-[3-(furan-2-yl)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=1)=CC=CC=1C1=CC=CO1 TUGJBGFXDURIOG-UHFFFAOYSA-N 0.000 claims description 4
UTXSNSLGSDYHIB-UHFFFAOYSA-N 2-[6-chloro-2-[4-(difluoromethoxy)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(OC(F)F)C=C1 UTXSNSLGSDYHIB-UHFFFAOYSA-N 0.000 claims description 4
125000000068 chlorophenyl group Chemical group 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 4
238000006460 hydrolysis reaction Methods 0.000 claims description 4
XMVXNDOSEHYPJT-UHFFFAOYSA-N methyl 2-[2-(3-bromobenzoyl)-6-chloro-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC(Br)=C1 XMVXNDOSEHYPJT-UHFFFAOYSA-N 0.000 claims description 4
KYYDRJQWKPOSCU-UHFFFAOYSA-N methyl 2-[2-(4-bromobenzoyl)-6-chloro-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Br)C=C1 KYYDRJQWKPOSCU-UHFFFAOYSA-N 0.000 claims description 4
PSBBVSOANYYNTM-UHFFFAOYSA-N methyl 2-[2-(4-chlorobenzoyl)-6-methyl-1h-indol-3-yl]acetate Chemical compound N1C2=CC(C)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C=C1 PSBBVSOANYYNTM-UHFFFAOYSA-N 0.000 claims description 4
KZTDXMVQAZALCQ-UHFFFAOYSA-N methyl 2-[2-(4-tert-butylpyridine-2-carbonyl)-6-chloro-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(C(C)(C)C)=CC=N1 KZTDXMVQAZALCQ-UHFFFAOYSA-N 0.000 claims description 4
AZBILHAGGANXIZ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(3-chloro-4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)OC)=C1Cl AZBILHAGGANXIZ-UHFFFAOYSA-N 0.000 claims description 4
QSXVQLOWMJUHFZ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-methoxypyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(OC)=CC=N1 QSXVQLOWMJUHFZ-UHFFFAOYSA-N 0.000 claims description 4
SKZPHUUTOZJTSU-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-propylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCCC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)OC)=C1 SKZPHUUTOZJTSU-UHFFFAOYSA-N 0.000 claims description 4
BLOBRKIQTLOWAD-UHFFFAOYSA-N methyl 2-[5-ethyl-2-(4-ethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(CC)=CC=C3N2)CC(=O)OC)=C1 BLOBRKIQTLOWAD-UHFFFAOYSA-N 0.000 claims description 4
QUCDPBGVAQJKOG-UHFFFAOYSA-N methyl 2-[6-chloro-2-(3-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=NC=CC=C1C QUCDPBGVAQJKOG-UHFFFAOYSA-N 0.000 claims description 4
GGIBSHMJJCSEDQ-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-cyanobenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(C#N)C=C1 GGIBSHMJJCSEDQ-UHFFFAOYSA-N 0.000 claims description 4
UXXFHVKVHYEFMY-UHFFFAOYSA-N methyl 2-[6-chloro-2-(5-methyl-1,2-oxazole-3-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C=1C=C(C)ON=1 UXXFHVKVHYEFMY-UHFFFAOYSA-N 0.000 claims description 4
KWKITUBBQQAKPI-UHFFFAOYSA-N methyl 2-[6-ethyl-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(CC)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC=N1 KWKITUBBQQAKPI-UHFFFAOYSA-N 0.000 claims description 4
MUKSXUCOPSOZLA-UHFFFAOYSA-N methyl 2-[6-methoxy-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(OC)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC(C)=CC=N1 MUKSXUCOPSOZLA-UHFFFAOYSA-N 0.000 claims description 4
125000006384 methylpyridyl group Chemical group 0.000 claims description 4
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 3
SXNJXLBASRRSQG-UHFFFAOYSA-N 2-[5-chloro-2-(5-methyl-1,2-oxazole-3-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound O1C(C)=CC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=N1 SXNJXLBASRRSQG-UHFFFAOYSA-N 0.000 claims description 3
RXESIXLBZIGNDS-UHFFFAOYSA-N 2-[6-chloro-2-(pyridine-3-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CN=C1 RXESIXLBZIGNDS-UHFFFAOYSA-N 0.000 claims description 3
LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 claims description 3
235000019270 ammonium chloride Nutrition 0.000 claims description 3
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 3
125000004438 haloalkoxy group Chemical group 0.000 claims description 3
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
NDUQBKJUKWVOLT-UHFFFAOYSA-N methyl 2-[5-chloro-2-(1-methylimidazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=CN1C NDUQBKJUKWVOLT-UHFFFAOYSA-N 0.000 claims description 3
LPWYMMCSDUGWEC-UHFFFAOYSA-N methyl 2-[6-chloro-2-(3-methoxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC(OC)=C1 LPWYMMCSDUGWEC-UHFFFAOYSA-N 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
235000015424 sodium Nutrition 0.000 claims description 3
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
GOTBESRGPQTYNI-UHFFFAOYSA-N 1-(3-aminopyrrolidin-1-yl)-2-[5-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]ethanone Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)N2CC(N)CC2)=C1 GOTBESRGPQTYNI-UHFFFAOYSA-N 0.000 claims description 2
RGCXAYMJOQCZEO-UHFFFAOYSA-N 2-(2-benzoyl-4,5-dichloro-1h-indol-3-yl)acetic acid Chemical compound N1C2=CC=C(Cl)C(Cl)=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 RGCXAYMJOQCZEO-UHFFFAOYSA-N 0.000 claims description 2
MZYCQNRHBIVTKU-UHFFFAOYSA-N 2-(2-benzoyl-4,6-dichloro-1h-indol-3-yl)acetic acid Chemical compound N1C2=CC(Cl)=CC(Cl)=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 MZYCQNRHBIVTKU-UHFFFAOYSA-N 0.000 claims description 2
MVQGYQWCZHUOJM-UHFFFAOYSA-N 2-(2-benzoyl-5,6-dichloro-1h-indol-3-yl)acetic acid Chemical compound N1C2=CC(Cl)=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 MVQGYQWCZHUOJM-UHFFFAOYSA-N 0.000 claims description 2
ZNZUFZCXNCWVSW-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CC1=C(C(=O)C=2C=CC=CC=2)NC2=CC(Cl)=CC=C12 ZNZUFZCXNCWVSW-UHFFFAOYSA-N 0.000 claims description 2
IJKQRSQWFATMPA-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-1-morpholin-4-ylethanone Chemical compound C=1C=CC=CC=1C(=O)C=1NC2=CC(Cl)=CC=C2C=1CC(=O)N1CCOCC1 IJKQRSQWFATMPA-UHFFFAOYSA-N 0.000 claims description 2
VDOYJRHOWGHVDP-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-1-piperidin-1-ylethanone Chemical compound C=1C=CC=CC=1C(=O)C=1NC2=CC(Cl)=CC=C2C=1CC(=O)N1CCCCC1 VDOYJRHOWGHVDP-UHFFFAOYSA-N 0.000 claims description 2
ANFKJYNQQBDFQQ-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-n-(2-hydroxyethyl)acetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)NCCO)=C1C(=O)C1=CC=CC=C1 ANFKJYNQQBDFQQ-UHFFFAOYSA-N 0.000 claims description 2
UVLYQZVWHWTARZ-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)acetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)N)=C1C(=O)C1=CC=CC=C1 UVLYQZVWHWTARZ-UHFFFAOYSA-N 0.000 claims description 2
UAPYAWJXCXJOOH-UHFFFAOYSA-N 2-(2-benzoyl-7-chloro-1h-indol-3-yl)acetic acid Chemical compound N1C2=C(Cl)C=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=CC=C1 UAPYAWJXCXJOOH-UHFFFAOYSA-N 0.000 claims description 2
RCUWSHCBWXTKAZ-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-5-ethyl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C2=CC(CC)=CC=C2NC=1C(=O)C1=CC=C(Cl)C=C1 RCUWSHCBWXTKAZ-UHFFFAOYSA-N 0.000 claims description 2
MYDDXBOZCRRFSN-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-6-fluoro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(F)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 MYDDXBOZCRRFSN-UHFFFAOYSA-N 0.000 claims description 2
DNKJFSFXUTXMRH-UHFFFAOYSA-N 2-[5-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]-1-piperazin-1-ylethanone Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)N2CCNCC2)=C1 DNKJFSFXUTXMRH-UHFFFAOYSA-N 0.000 claims description 2
HDVZQJHVCWIRDQ-UHFFFAOYSA-N 2-[5-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]-n-methoxyacetamide Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)NOC)=C1C(=O)C1=CC(C)=CC=N1 HDVZQJHVCWIRDQ-UHFFFAOYSA-N 0.000 claims description 2
RFXXZTGUGKQIBZ-UHFFFAOYSA-N 2-[6-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]-n-methylacetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)NC)=C1C(=O)C1=CC(C)=CC=N1 RFXXZTGUGKQIBZ-UHFFFAOYSA-N 0.000 claims description 2
SZQLJRUPQGEKLC-UHFFFAOYSA-N 2-[6-fluoro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC=C(F)C=C3N2)CC(O)=O)=C1 SZQLJRUPQGEKLC-UHFFFAOYSA-N 0.000 claims description 2
CQODGVQBRIGKLJ-UHFFFAOYSA-L [Na+].[Na+].[O-]OOO[O-] Chemical compound [Na+].[Na+].[O-]OOO[O-] CQODGVQBRIGKLJ-UHFFFAOYSA-L 0.000 claims description 2
125000005605 benzo group Chemical group 0.000 claims description 2
125000004799 bromophenyl group Chemical group 0.000 claims description 2
125000006378 chloropyridyl group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000001207 fluorophenyl group Chemical group 0.000 claims description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 2
USPPGUUYZTYASB-UHFFFAOYSA-N methyl 2-[2-(4-ethylpyridine-2-carbonyl)-5-(trifluoromethoxy)-1h-indol-3-yl]acetate Chemical compound CCC1=CC=NC(C(=O)C2=C(C3=CC(OC(F)(F)F)=CC=C3N2)CC(=O)OC)=C1 USPPGUUYZTYASB-UHFFFAOYSA-N 0.000 claims description 2
FQVQQFDRSSGGSF-UHFFFAOYSA-N methyl 2-[2-(4-tert-butylpyridine-2-carbonyl)-5-chloro-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C(C)(C)C)=CC=N1 FQVQQFDRSSGGSF-UHFFFAOYSA-N 0.000 claims description 2
JGOTXUXKJGOIQO-UHFFFAOYSA-N methyl 2-[5-chloro-2-(1,3-thiazole-5-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CN=CS1 JGOTXUXKJGOIQO-UHFFFAOYSA-N 0.000 claims description 2
UJIDTXABWKUPHM-UHFFFAOYSA-N methyl 2-[5-chloro-2-(1-methylpyrrole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=CN1C UJIDTXABWKUPHM-UHFFFAOYSA-N 0.000 claims description 2
KONVFODCBRCJDU-UHFFFAOYSA-N methyl 2-[5-chloro-2-(1h-imidazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=CN1 KONVFODCBRCJDU-UHFFFAOYSA-N 0.000 claims description 2
HYYXMFSXWPERMY-UHFFFAOYSA-N methyl 2-[5-chloro-2-(3,4-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=CC(C)=C1C HYYXMFSXWPERMY-UHFFFAOYSA-N 0.000 claims description 2
HYGYCIODLZLYOM-UHFFFAOYSA-N methyl 2-[5-chloro-2-(3-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=NC=CC=C1C HYGYCIODLZLYOM-UHFFFAOYSA-N 0.000 claims description 2
LMVBAOMTFGSKAJ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-methylthiadiazole-5-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C=1SN=NC=1C LMVBAOMTFGSKAJ-UHFFFAOYSA-N 0.000 claims description 2
KDRYJJNBCUIKEJ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(4-propan-2-ylpyridine-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C1=CC(C(C)C)=CC=N1 KDRYJJNBCUIKEJ-UHFFFAOYSA-N 0.000 claims description 2
DXAVSTNJPVXKGJ-UHFFFAOYSA-N methyl 2-[5-chloro-2-(5-methyl-1,2-oxazole-3-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)OC)=C1C(=O)C=1C=C(C)ON=1 DXAVSTNJPVXKGJ-UHFFFAOYSA-N 0.000 claims description 2
JTFQNVZLKRYIFP-UHFFFAOYSA-N methyl 2-[5-tert-butyl-2-(4-chlorobenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC=C(C(C)(C)C)C=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C=C1 JTFQNVZLKRYIFP-UHFFFAOYSA-N 0.000 claims description 2
BHTDMHWIOFGFNV-UHFFFAOYSA-N methyl 2-[6-chloro-2-(1-methylimidazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=NC=CN1C BHTDMHWIOFGFNV-UHFFFAOYSA-N 0.000 claims description 2
PASSHDSAHRZPPN-UHFFFAOYSA-N methyl 2-[6-chloro-2-(1h-imidazole-2-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=NC=CN1 PASSHDSAHRZPPN-UHFFFAOYSA-N 0.000 claims description 2
YTQICMLHOTVTGX-UHFFFAOYSA-N methyl 2-[6-chloro-2-(2-methoxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC=C1OC YTQICMLHOTVTGX-UHFFFAOYSA-N 0.000 claims description 2
USOVMTGSFDDXEK-UHFFFAOYSA-N methyl 2-[6-chloro-2-(3-hydroxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CC(O)=C1 USOVMTGSFDDXEK-UHFFFAOYSA-N 0.000 claims description 2
YUEJHYAVTIHQSI-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-chloro-3-fluorobenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(Cl)C(F)=C1 YUEJHYAVTIHQSI-UHFFFAOYSA-N 0.000 claims description 2
QVMSZGMBZYHKPZ-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-hydroxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(O)C=C1 QVMSZGMBZYHKPZ-UHFFFAOYSA-N 0.000 claims description 2
RJRUUGYSMGYRCD-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-methylthiadiazole-5-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C=1SN=NC=1C RJRUUGYSMGYRCD-UHFFFAOYSA-N 0.000 claims description 2
NBZLKORWWGJUCW-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-nitrobenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C([N+]([O-])=O)C=C1 NBZLKORWWGJUCW-UHFFFAOYSA-N 0.000 claims description 2
OGFYTEFXHMAWGJ-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-phenylbenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 OGFYTEFXHMAWGJ-UHFFFAOYSA-N 0.000 claims description 2
PKWKTFRNRKQFMV-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-propan-2-yloxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=C(OC(C)C)C=C1 PKWKTFRNRKQFMV-UHFFFAOYSA-N 0.000 claims description 2
NAZWSKAQINVPPF-UHFFFAOYSA-N methyl 2-[6-chloro-2-(cyclobutanecarbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1CCC1 NAZWSKAQINVPPF-UHFFFAOYSA-N 0.000 claims description 2
YKEKTHVZPNVZGE-UHFFFAOYSA-N methyl 2-[6-chloro-2-(cyclopropanecarbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1CC1 YKEKTHVZPNVZGE-UHFFFAOYSA-N 0.000 claims description 2
ZCCHGFIMHYCBLH-UHFFFAOYSA-N methyl 2-[6-chloro-2-(pyridine-3-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=CN=C1 ZCCHGFIMHYCBLH-UHFFFAOYSA-N 0.000 claims description 2
DCDHPFYJYZRESQ-UHFFFAOYSA-N methyl 2-[6-chloro-2-(pyridine-4-carbonyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C1=CC=NC=C1 DCDHPFYJYZRESQ-UHFFFAOYSA-N 0.000 claims description 2
UTYMXLBNRBBWHU-UHFFFAOYSA-N methyl 2-[6-chloro-2-[3-(furan-2-yl)benzoyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=1)=CC=CC=1C1=CC=CO1 UTYMXLBNRBBWHU-UHFFFAOYSA-N 0.000 claims description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
239000011541 reaction mixture Substances 0.000 claims description 2
125000003944 tolyl group Chemical group 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 29
150000002431 hydrogen Chemical class 0.000 claims 7
YCABRYINYKIBLF-UHFFFAOYSA-N 2-[6-chloro-2-[4-(furan-2-yl)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1C1=CC=CO1 YCABRYINYKIBLF-UHFFFAOYSA-N 0.000 claims 6
150000001335 aliphatic alkanes Chemical class 0.000 claims 3
AFENDVZTGBZOCS-UHFFFAOYSA-N methyl 2-[6-chloro-2-[4-(furan-2-yl)benzoyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=C1)=CC=C1C1=CC=CO1 AFENDVZTGBZOCS-UHFFFAOYSA-N 0.000 claims 3
238000005406 washing Methods 0.000 claims 3
JBMBFPSWAHDWJN-UHFFFAOYSA-N 2-[5-chloro-2-[5-(trifluoromethyl)pyridine-2-carbonyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=C(Cl)C=C2C(CC(=O)O)=C1C(=O)C1=CC=C(C(F)(F)F)C=N1 JBMBFPSWAHDWJN-UHFFFAOYSA-N 0.000 claims 2
BFDZSIVADHPBDX-UHFFFAOYSA-N 2-[6-chloro-2-(4-pyridin-3-ylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1C1=CC=CN=C1 BFDZSIVADHPBDX-UHFFFAOYSA-N 0.000 claims 2
JMUWFNFIDYAFKI-UHFFFAOYSA-N 2-[6-chloro-2-(4-thiophen-2-ylbenzoyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1C1=CC=CS1 JMUWFNFIDYAFKI-UHFFFAOYSA-N 0.000 claims 2
BFUXULXWBWSQGU-UHFFFAOYSA-N 2-[6-chloro-2-[4-(1,3-thiazol-2-yl)benzoyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)O)=C1C(=O)C(C=C1)=CC=C1C1=NC=CS1 BFUXULXWBWSQGU-UHFFFAOYSA-N 0.000 claims 2
FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims 2
BOBHNBJTSRMAFB-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-n,n-dimethylacetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)N(C)C)=C1C(=O)C1=CC=CC=C1 BOBHNBJTSRMAFB-UHFFFAOYSA-N 0.000 claims 1
DUPJOZOZJXDOIP-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-n-methylacetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)NC)=C1C(=O)C1=CC=CC=C1 DUPJOZOZJXDOIP-UHFFFAOYSA-N 0.000 claims 1
MWJHRMDTJLPMNA-UHFFFAOYSA-N 2-[2-(4-chlorobenzoyl)-6-(trifluoromethyl)-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC(C(F)(F)F)=CC=C2C(CC(=O)O)=C1C(=O)C1=CC=C(Cl)C=C1 MWJHRMDTJLPMNA-UHFFFAOYSA-N 0.000 claims 1
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
241001122767 Theaceae Species 0.000 claims 1
125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
XIFUHFKNCPWNAB-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-pyridin-3-ylbenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=C1)=CC=C1C1=CC=CN=C1 XIFUHFKNCPWNAB-UHFFFAOYSA-N 0.000 claims 1
NHJAPVCXNMOQLP-UHFFFAOYSA-N methyl 2-[6-chloro-2-(4-thiophen-2-ylbenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=C1)=CC=C1C1=CC=CS1 NHJAPVCXNMOQLP-UHFFFAOYSA-N 0.000 claims 1
SAIQWUFFXIPRSR-UHFFFAOYSA-N methyl 2-[6-chloro-2-[4-(1,3-thiazol-2-yl)benzoyl]-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=C1)=CC=C1C1=NC=CS1 SAIQWUFFXIPRSR-UHFFFAOYSA-N 0.000 claims 1
WFUDNLGVIXCXQY-UHFFFAOYSA-N n-(2-aminoethyl)-2-[5-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]acetamide Chemical compound CC1=CC=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(=O)NCCN)=C1 WFUDNLGVIXCXQY-UHFFFAOYSA-N 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
239000002585 base Substances 0.000 description 54
235000011054 acetic acid Nutrition 0.000 description 47
229960000583 acetic acid Drugs 0.000 description 47
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 29
239000003795 chemical substances by application Substances 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
230000035484 reaction time Effects 0.000 description 10
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
230000004054 inflammatory process Effects 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
238000010992 reflux Methods 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 6
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 6
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
229910052684 Cerium Inorganic materials 0.000 description 5
229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
FZIZEIAMIREUTN-UHFFFAOYSA-N azane;cerium(3+) Chemical compound N.[Ce+3] FZIZEIAMIREUTN-UHFFFAOYSA-N 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000012442 inert solvent Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
201000008482 osteoarthritis Diseases 0.000 description 5
230000036407 pain Effects 0.000 description 5
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
206010013935 Dysmenorrhoea Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
230000000340 anti-metabolite Effects 0.000 description 3
229940100197 antimetabolite Drugs 0.000 description 3
239000002256 antimetabolite Substances 0.000 description 3
229940114079 arachidonic acid Drugs 0.000 description 3
235000021342 arachidonic acid Nutrition 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000004093 hydrolase inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
239000006072 paste Substances 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229960003975 potassium Drugs 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940127293 prostanoid Drugs 0.000 description 3
150000003814 prostanoids Chemical class 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000000829 suppository Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
238000001308 synthesis method Methods 0.000 description 3
PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
JOPSSWGWLCLPPF-RUDMXATFSA-N 5-[2-(2-carboxyethyl)-3-[(e)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1\C=C\CCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-RUDMXATFSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
206010006811 Bursitis Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
208000005171 Dysmenorrhea Diseases 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
206010042674 Swelling Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
150000001266 acyl halides Chemical class 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000003513 alkali Substances 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
229960000640 dactinomycin Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229960003559 enprostil Drugs 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
108010072713 leukotriene A4 hydrolase Proteins 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 2
AHSBSUVHXDIAEY-UHFFFAOYSA-K manganese(iii) acetate Chemical compound [Mn+3].CC([O-])=O.CC([O-])=O.CC([O-])=O AHSBSUVHXDIAEY-UHFFFAOYSA-K 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 description 2
229960005249 misoprostol Drugs 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
231100000417 nephrotoxicity Toxicity 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
201000003068 rheumatic fever Diseases 0.000 description 2
NMAOJFAMEOVURT-RTKIROINSA-N rosaprostol Chemical compound CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC(O)=O NMAOJFAMEOVURT-RTKIROINSA-N 0.000 description 2
229950003055 rosaprostol Drugs 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
XKKGMVDIONCFKP-UHFFFAOYSA-N (2-butyl-4-methoxynaphthalen-1-yl) acetate Chemical compound C1=CC=CC2=C(OC(C)=O)C(CCCC)=CC(OC)=C21 XKKGMVDIONCFKP-UHFFFAOYSA-N 0.000 description 1
ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
LULLRDASRDVYPV-BYPYZUCNSA-N (2s)-2-amino-2-(3-aminopropoxy)acetic acid Chemical compound NCCCO[C@H](N)C(O)=O LULLRDASRDVYPV-BYPYZUCNSA-N 0.000 description 1
YEORLXJBCPPSOC-SSDOTTSWSA-N (2s)-2-amino-5-(diaminomethylideneamino)-2-(difluoromethyl)pentanoic acid Chemical compound NC(=N)NCCC[C@@](N)(C(F)F)C(O)=O YEORLXJBCPPSOC-SSDOTTSWSA-N 0.000 description 1
IEFNEZUQHDYNRM-UHFFFAOYSA-L (4-azanidyl-2-methylbutyl)azanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC(C)CC[NH-].[O-]C(=O)C1(C([O-])=O)CCC1 IEFNEZUQHDYNRM-UHFFFAOYSA-L 0.000 description 1
WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
LKBBOPGQDRPCDS-YAOXHJNESA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
125000004846 (C1-C4) allyl group Chemical group 0.000 description 1
125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
AIOFTOLPMOTZKD-OPVFONCOSA-N (z)-7-[(1r,2r,3r,5r)-5-chloro-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](Cl)[C@@H]1C\C=C/CCCC(O)=O AIOFTOLPMOTZKD-OPVFONCOSA-N 0.000 description 1
UJFDLBWYYFZXDS-LEENOTDESA-N (z)-7-[(1s,2s,3s)-2-[(e,3s)-5-ethoxy-3-hydroxy-4,4-dimethylpent-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCOCC(C)(C)[C@@H](O)\C=C\[C@@H]1[C@@H](O)CC(=O)[C@H]1C\C=C/CCCC(O)=O UJFDLBWYYFZXDS-LEENOTDESA-N 0.000 description 1
BUMMZWFWCNQFPS-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-n,n-di(propan-2-yl)benzamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 BUMMZWFWCNQFPS-BTJKTKAUSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
YJZJEQBSODVMTH-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea Chemical compound OCCNC(=O)N(N=O)CCCl YJZJEQBSODVMTH-UHFFFAOYSA-N 0.000 description 1
BQIFCAGMUAMYDV-DHBOJHSNSA-N 1-(2-chloroethyl)-3-[(2r,6s)-2,6-dihydroxycyclohexyl]-1-nitrosourea Chemical compound O[C@H]1CCC[C@@H](O)C1NC(=O)N(CCCl)N=O BQIFCAGMUAMYDV-DHBOJHSNSA-N 0.000 description 1
RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
VSWUWZJXMRATTF-UHFFFAOYSA-N 1-propan-2-yl-1h-pyrrolizine Chemical compound C1=CC=C2C(C(C)C)C=CN21 VSWUWZJXMRATTF-UHFFFAOYSA-N 0.000 description 1
XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 1
UFMKISRHXWKTOY-UHFFFAOYSA-N 2,3-dihydro-1h-isoindol-1-ol Chemical compound C1=CC=C2C(O)NCC2=C1 UFMKISRHXWKTOY-UHFFFAOYSA-N 0.000 description 1
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
XYEOBYLFEHWXHW-UHFFFAOYSA-N 2-(2-benzoyl-6-chloro-1h-indol-3-yl)-n-methoxy-n-methylacetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)N(C)OC)=C1C(=O)C1=CC=CC=C1 XYEOBYLFEHWXHW-UHFFFAOYSA-N 0.000 description 1
UIJWMSUSZQORDJ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 UIJWMSUSZQORDJ-UHFFFAOYSA-N 0.000 description 1
HGLRIYIVJRXBQM-UHFFFAOYSA-N 2-[2-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxyethyl]-1,3-thiazinane-4-carboxylic acid Chemical compound ClCCN(CCCl)P(=O)(N)OCCC1NC(C(O)=O)CCS1 HGLRIYIVJRXBQM-UHFFFAOYSA-N 0.000 description 1
ICZQBYYTECBHFE-UHFFFAOYSA-N 2-[5-chloro-2-(4,6-dimethylpyridine-2-carbonyl)-1h-indol-3-yl]acetic acid Chemical compound CC1=CC(C)=NC(C(=O)C2=C(C3=CC(Cl)=CC=C3N2)CC(O)=O)=C1 ICZQBYYTECBHFE-UHFFFAOYSA-N 0.000 description 1
WLYLIKHLRGEHAN-UHFFFAOYSA-N 2-[6-chloro-2-(4-methylpyridine-2-carbonyl)-1h-indol-3-yl]-n,n-dimethylacetamide Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)N(C)C)=C1C(=O)C1=CC(C)=CC=N1 WLYLIKHLRGEHAN-UHFFFAOYSA-N 0.000 description 1
PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
VBZOUUJVGADJBK-UHFFFAOYSA-N 2-bromopropanedioic acid Chemical compound OC(=O)C(Br)C(O)=O VBZOUUJVGADJBK-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
LBYVZRFDLNAPRC-UHFFFAOYSA-N 2-sulfanylguanidine Chemical compound NC(=N)NS LBYVZRFDLNAPRC-UHFFFAOYSA-N 0.000 description 1
UKVFKRGLLNSVNJ-UHFFFAOYSA-L 3,5-dichloro-4-[1,2-diamino-2-(2,6-dichloro-4-hydroxyphenyl)ethyl]phenol;platinum(2+);sulfate;dihydrate Chemical compound O.O.[Pt+2].[O-]S([O-])(=O)=O.ClC=1C=C(O)C=C(Cl)C=1C(N)C(N)C1=C(Cl)C=C(O)C=C1Cl UKVFKRGLLNSVNJ-UHFFFAOYSA-L 0.000 description 1
IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
MIEMDQVNFRNROW-UHFFFAOYSA-N 3-[[5-[10-[4-(dimethylamino)-5-hydroxy-4,6-dimethyloxan-2-yl]-8-[4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-11-hydroxy-5-methyl-2-[2-methyl-3-(3-methyloxiran-2-yl)oxiran-2-yl]-4,7-dioxo-12h-naphtho[3,2-h]chromen-12-yl]-1-hydroxypyrrole-2-carbonyl]amin Chemical compound CC1OC1C1C(C=2OC3=C4C(C=5N(C(C(=O)NCCC(O)=O)=CC=5)O)C5=C(O)C(C6OC(C)C(O)C(C)(C6)N(C)C)=CC(=C5C(=O)C4=CC(C)=C3C(=O)C=2)C2OC(C)C(O)C(C2)N(C)C)(C)O1 MIEMDQVNFRNROW-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2s,3s,4s)-3-hydroxy-2-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
KRCUWCAUDKTMPB-UHFFFAOYSA-N 4-[[n-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN(C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1)CC1=CC=CC(F)=C1 KRCUWCAUDKTMPB-UHFFFAOYSA-N 0.000 description 1
XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
MRFRLYAOBSTHHU-UHFFFAOYSA-N 6-amino-3-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one;hydrochloride Chemical compound Cl.O=C1NC(N)=NCN1C1C(O)C(O)C(CO)O1 MRFRLYAOBSTHHU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
BGYNLOSBKBOJJD-IUCAKERBSA-N Aeroplysinin 1 Chemical compound COC1=C(Br)[C@H](O)[C@](O)(CC#N)C=C1Br BGYNLOSBKBOJJD-IUCAKERBSA-N 0.000 description 1
QMGUSPDJTPDFSF-UHFFFAOYSA-N Aldophosphamide Chemical class ClCCN(CCCl)P(=O)(N)OCCC=O QMGUSPDJTPDFSF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
108010029748 Angiostat Proteins 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
TYGJUQYJMIOZLZ-VTYVZKAMSA-N Antibiotic BU 2867TA Natural products O=C(N[C@H]1C(=O)N[C@@H](C)/C=C\C(=O)NCC[C@@H](O)C1)[C@@H](NC(=O)/C=C/C=C\CCCCCCC)[C@@H](O)C TYGJUQYJMIOZLZ-VTYVZKAMSA-N 0.000 description 1
OSEDIRANPWGFRX-BONVTDFDSA-N Antibiotic DOB 41 Natural products O([C@@H](C)c1c2nc3c(c(C(=O)O)ccc3)nc2ccc1)C(=O)[C@@H](OC)CO OSEDIRANPWGFRX-BONVTDFDSA-N 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
DGGZCXUXASNDAC-QQNGCVSVSA-N C-1027 chromophore Chemical compound COc1cc2OC(=C)C(=O)Nc2c(c1)C(=O)O[C@H]3COC(=O)C[C@H](N)c4cc(O)c(O[C@@H]5C#C\C=C\3/C#CC6=CC=C[C@]56O[C@@H]7OC(C)(C)[C@H]([C@@H](O)[C@H]7O)N(C)C)c(Cl)c4 DGGZCXUXASNDAC-QQNGCVSVSA-N 0.000 description 1
SLULCLFNMQXCGB-UHFFFAOYSA-N CN(C)C1=[C-]C2=CC=CC=C2C=C1.[Na+] Chemical compound CN(C)C1=[C-]C2=CC=CC=C2C=C1.[Na+] SLULCLFNMQXCGB-UHFFFAOYSA-N 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
ZDJRSUWWMAYYID-ZXHXBDCOSA-N Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@]([C@@H](C3=C(O)C=4C(=O)C5=CC=CC(O)=C5C(=O)C=4C(O)=C32)O)(O)CC)CCOCC1 Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@]([C@@H](C3=C(O)C=4C(=O)C5=CC=CC(O)=C5C(=O)C=4C(O)=C32)O)(O)CC)CCOCC1 ZDJRSUWWMAYYID-ZXHXBDCOSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
102100027995 Collagenase 3 Human genes 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000033131 Congenital factor II deficiency Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000007646 Hypoprothrombinemias Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000021908 Myocardial disease Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
WPMGFKKSCCXUAK-YFZUDYRPSA-N Nbeta-acetylstreptothricin D Chemical compound NCCC[C@H](N)CC(=O)NCCC[C@H](N)CC(=O)NCCC[C@H](NC(=O)C)CC(=O)N[C@@H]1[C@H](O)[C@@H](OC(N)=O)[C@@H](CO)O[C@H]1NC1=N[C@@H]2C(=O)NC[C@@H](O)[C@H]2N1 WPMGFKKSCCXUAK-YFZUDYRPSA-N 0.000 description 1
208000005289 Neoplastic Cell Transformation Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
229940116685 Neuropeptide receptor antagonist Drugs 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229940123134 Nitric oxide inhibitor Drugs 0.000 description 1
LKBBOPGQDRPCDS-UHFFFAOYSA-N Oxaunomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N)C(O)C(C)O1 LKBBOPGQDRPCDS-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
101710148027 Ribulose bisphosphate carboxylase/oxygenase activase 1, chloroplastic Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
PBRHVAKBKPQZAF-CMMHMAGGSA-N [(1s)-2-[[(1e)-1-[(1s,2r,3r)-3-acetyloxy-2-hydroxy-5-azabicyclo[3.1.0]hexan-4-ylidene]-2-oxo-2-(2-oxopropylamino)ethyl]amino]-1-[(2s)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate Chemical compound C[C@@]1([C@@H](C(=O)N\C(C(=O)NCC(C)=O)=C/2N3C[C@H]3[C@@H](O)[C@@H]\2OC(C)=O)OC(=O)C=2C=C(C=C3C(C)=CC=CC3=2)OC)CO1 PBRHVAKBKPQZAF-CMMHMAGGSA-N 0.000 description 1
LJBKHHZPVCABCX-ZYUZMQFOSA-N [(2r,3r,4r,5r)-2,5-dihydroxy-3,4-dimethoxy-6-methylsulfonyloxyhexyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@@H](OC)[C@H](OC)[C@H](O)COS(C)(=O)=O LJBKHHZPVCABCX-ZYUZMQFOSA-N 0.000 description 1
DJUWKQJNJVMFIU-IHAUNJBESA-N [(2r,3r,4s,5r)-3,4,5-triacetyloxy-6-[bis(2-chloroethyl)amino]oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(N(CCCl)CCCl)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O DJUWKQJNJVMFIU-IHAUNJBESA-N 0.000 description 1
YJHYHDSHHWKEIS-CJUKMMNNSA-N [(4S,6S,7R,8S)-11-(2-hydroxyethoxy)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate Chemical compound CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(OCCO)=C(C)C1=O YJHYHDSHHWKEIS-CJUKMMNNSA-N 0.000 description 1
LUOUCHOLMUUZBO-SVSXJNCISA-N [4-[(1e,3e)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate Chemical compound C1=C(OC)C(OC(=O)OCC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 LUOUCHOLMUUZBO-SVSXJNCISA-N 0.000 description 1
GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
MHVFYGIQJNFWGQ-UHFFFAOYSA-N [[4,6-bis[hydroxymethyl(methyl)amino]-1,3,5-triazin-2-yl]-methylamino]methanol Chemical compound OCN(C)C1=NC(N(C)CO)=NC(N(C)CO)=N1 MHVFYGIQJNFWGQ-UHFFFAOYSA-N 0.000 description 1
JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
229960004176 aclarubicin Drugs 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
239000011795 alpha-carotene Substances 0.000 description 1
ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
235000003903 alpha-carotene Nutrition 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940024548 aluminum oxide Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000007131 anti Alzheimer effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
108010005272 antineoplaston A2 Proteins 0.000 description 1
108010005286 antineoplaston A3 Proteins 0.000 description 1
108010005569 antineoplaston A5 Proteins 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229950002312 arbaprostil Drugs 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
PBRHVAKBKPQZAF-UHFFFAOYSA-N azinomycin A Natural products C=12C=CC=C(C)C2=CC(OC)=CC=1C(=O)OC(C(=O)NC(C(=O)NCC(C)=O)=C1N2CC2C(O)C1OC(C)=O)C1(C)CO1 PBRHVAKBKPQZAF-UHFFFAOYSA-N 0.000 description 1
108010010080 azinomycin A Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
ZNDJOCJUBZZAMN-USYHLRJESA-N bmy-25067 Chemical compound C([C@@H]1N[C@@H]1[C@@]1([C@@H]2COC(N)=O)OC)N1C(C(C=1C)=O)=C2C(=O)C=1NCCSSC1=CC=C([N+]([O-])=O)C=C1 ZNDJOCJUBZZAMN-USYHLRJESA-N 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229950006427 bunaprolast Drugs 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229950009338 caracemide Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
UUCQYXYIXMAACT-UHFFFAOYSA-N carboxysulfonyloxysulfonylformic acid Chemical compound OC(=O)S(=O)(=O)OS(=O)(=O)C(O)=O UUCQYXYIXMAACT-UHFFFAOYSA-N 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
ORJRBJIJTSDUCG-UHFFFAOYSA-N cervinomycin a2 Chemical compound C1C2(C)OCCN2C(=O)C2=C(O)C3=C(C(=O)C4=C(OC=5C=C(C(=CC=5C4=O)OC)OC)C4=O)C4=CC=C3C=C21 ORJRBJIJTSDUCG-UHFFFAOYSA-N 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000003426 co-catalyst Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
239000000571 coke Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
BVQPGVHVDXIPJF-UHFFFAOYSA-L cyclohexane-1,2-diamine;hydron;2-[(2-phosphonatoacetyl)amino]butanedioate;platinum(2+) Chemical compound [H+].[H+].[Pt+2].NC1CCCCC1N.[O-]C(=O)CC(C([O-])=O)NC(=O)CP([O-])([O-])=O BVQPGVHVDXIPJF-UHFFFAOYSA-L 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
235000010300 dimethyl dicarbonate Nutrition 0.000 description 1
229950008992 dimoxaprost Drugs 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
PFWDHRASWSUTIA-KAFJHEIMSA-L disodium;(2s)-5-amino-5-oxo-2-[(2-phenylacetyl)amino]pentanoate;2-phenylacetate Chemical compound [Na+].[Na+].[O-]C(=O)CC1=CC=CC=C1.NC(=O)CC[C@@H](C([O-])=O)NC(=O)CC1=CC=CC=C1 PFWDHRASWSUTIA-KAFJHEIMSA-L 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
208000007784 diverticulitis Diseases 0.000 description 1
OSEDIRANPWGFRX-UHFFFAOYSA-N dob-41 Chemical compound C1=CC=C2N=C3C(C(C)OC(=O)C(CO)OC)=CC=CC3=NC2=C1C(O)=O OSEDIRANPWGFRX-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
229950010033 ebselen Drugs 0.000 description 1
FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
229950003860 elmustine Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229950007459 enisoprost Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
229950002017 esorubicin Drugs 0.000 description 1
PTUJLUSPXWWJSQ-KAOVMFEUSA-N esperamycin a1 Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1O[C@@H](C1\C=C/C#C[C@@]2(O)C3=C1)C3=C(NC(=O)OC)C(=O)[C@@H]2OC1OC(C)C(O)C(OC(=O)C=2C(=CC(OC)=C(OC)C=2)NC(=O)C(=C)OC)C1 PTUJLUSPXWWJSQ-KAOVMFEUSA-N 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
230000027950 fever generation Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
FBXPCVIKIBWXAE-ZJZHAWLTSA-N fk973 Chemical compound O1N2C[C@@H]3N(C(C)=O)[C@@H]3[C@]1(OC(C)=O)[C@@H](COC(N)=O)C1=C2C=C(C=O)C=C1OC(=O)C FBXPCVIKIBWXAE-ZJZHAWLTSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229950010404 fostriecin Drugs 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
229930189446 glidobactin Natural products 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
229930193320 herbimycin Natural products 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229930190064 illudin Natural products 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
150000002476 indolines Chemical class 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229950010897 iproplatin Drugs 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
BIOSTZMAOGCGSC-CYUGEGSCSA-N kt6149 Chemical compound C1N2C(C(C(C)=C(NCCSSCCNC(=O)CC[C@H](N)C(O)=O)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 BIOSTZMAOGCGSC-CYUGEGSCSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960005535 lidamycin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
229950010248 loretin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229950000547 mafosfamide Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
229960000816 magnesium hydroxide Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000017538 malonylation Effects 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950002676 menogaril Drugs 0.000 description 1
LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
AZVARJHZBXHUSO-DZQVEHCYSA-N methyl (1R,4R,12S)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-DZQVEHCYSA-N 0.000 description 1
CIBHDGPIOICRGX-ZQCHCGQNSA-N methyl (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-4-enoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC\C=C/CCC(=O)OC CIBHDGPIOICRGX-ZQCHCGQNSA-N 0.000 description 1
ILACFUSSEFWIQE-UHFFFAOYSA-N methyl 2-[6-chloro-2-(3-phenylmethoxybenzoyl)-1h-indol-3-yl]acetate Chemical compound N1C2=CC(Cl)=CC=C2C(CC(=O)OC)=C1C(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 ILACFUSSEFWIQE-UHFFFAOYSA-N 0.000 description 1
GGDWDKDPRJFMHD-ZXYUVVQBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-methoxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(OC)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC GGDWDKDPRJFMHD-ZXYUVVQBSA-N 0.000 description 1
229950000086 mexiprostil Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229950010913 mitolactol Drugs 0.000 description 1
VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
XEFNBUBDJCJOGM-OUJCMCIWSA-N n-[1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 XEFNBUBDJCJOGM-OUJCMCIWSA-N 0.000 description 1
FODMSVBVCPOQRL-UHFFFAOYSA-N n-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide;hydrochloride Chemical compound [Cl-].NC(N)=NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCC[NH3+] FODMSVBVCPOQRL-UHFFFAOYSA-N 0.000 description 1
BLSOATWWAGIRGE-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide;hydrochloride Chemical compound Cl.C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C BLSOATWWAGIRGE-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
229950003144 nocloprost Drugs 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960001528 oxymetazoline Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
229960003893 phenacetin Drugs 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
FGNPPWFDUWSHQL-UPEPMZDMSA-N pilatin Chemical compound O=CC1=C[C@]2(O)[C@H](OC(=O)/C=C/CCC)C(C)(C)C[C@@H]2[C@]23C(=O)O[C@H](O)[C@@]21C3 FGNPPWFDUWSHQL-UPEPMZDMSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
229950003608 prinomastat Drugs 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229960000786 propylhexedrine Drugs 0.000 description 1
JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
201000007183 prothrombin deficiency Diseases 0.000 description 1
229950010450 pseudophedrine Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000007154 radical cyclization reaction Methods 0.000 description 1
229960002185 ranimustine Drugs 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
239000011435 rock Chemical group 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229940083037 simethicone Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
QLUMLEDLZDMGDW-UHFFFAOYSA-N sodium;1h-naphthalen-1-ide Chemical compound [Na+].[C-]1=CC=CC2=CC=CC=C21 QLUMLEDLZDMGDW-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229950009641 sparsomycin Drugs 0.000 description 1
XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
229940032147 starch Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
108010021891 tallimustine Proteins 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229950010168 tauromustine Drugs 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
229960003676 tenidap Drugs 0.000 description 1
XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
229950009638 tepoxalin Drugs 0.000 description 1
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
229910000083 tin tetrahydride Inorganic materials 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
229940124279 traditional non-steroidal anti-inflammatory drug Drugs 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229960000833 xylometazoline Drugs 0.000 description 1
235000020138 yakult Nutrition 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
229960000641 zorubicin Drugs 0.000 description 1
FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BG104643A 1998-01-05 2000-07-28 2, 3-заместени индолови съединения като инхибитори на сох-2 BG104643A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB9800003		1998-01-05
PCT/IB1998/002065 WO1999035130A1 (fr)	1998-01-05	1998-12-18	Composes indole 2,3-substitues utilises comme inhibiteurs de cox-2

Publications (1)

Publication Number	Publication Date
BG104643A true BG104643A (bg)	2001-02-28

Family

ID=11004645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104643A BG104643A (bg)	1998-01-05	2000-07-28	2, 3-заместени индолови съединения като инхибитори на сох-2

Country Status (39)

Country	Link
US (1)	US6608070B1 (fr)
EP (1)	EP1045833B1 (fr)
JP (1)	JP3347136B2 (fr)
KR (1)	KR100404054B1 (fr)
CN (1)	CN1284064A (fr)
AP (1)	AP869A (fr)
AR (1)	AR016977A1 (fr)
AT (1)	ATE308519T1 (fr)
AU (1)	AU748107B2 (fr)
BG (1)	BG104643A (fr)
BR (1)	BR9813124A (fr)
CA (1)	CA2316863A1 (fr)
CO (1)	CO4970807A1 (fr)
DE (1)	DE69832200T2 (fr)
DZ (1)	DZ2700A1 (fr)
EA (1)	EA200000614A1 (fr)
ES (1)	ES2255190T3 (fr)
GT (1)	GT199800205A (fr)
HN (1)	HN1997000098A (fr)
HR (1)	HRP20000454A2 (fr)
HU (1)	HUP0102922A3 (fr)
ID (1)	ID24876A (fr)
IL (1)	IL136885A0 (fr)
IS (1)	IS5532A (fr)
MA (1)	MA24736A1 (fr)
NO (1)	NO20003451L (fr)
OA (1)	OA11441A (fr)
PA (1)	PA8466201A1 (fr)
PE (1)	PE20000055A1 (fr)
PL (1)	PL341696A1 (fr)
SA (1)	SA99191299A (fr)
SK (1)	SK9912000A3 (fr)
TN (1)	TNSN99001A1 (fr)
TR (1)	TR200001906T2 (fr)
TW (1)	TW436482B (fr)
UY (2)	UY25332A1 (fr)
WO (1)	WO1999035130A1 (fr)
YU (1)	YU41600A (fr)
ZA (1)	ZA9911B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6555540B1 (en) *	1999-06-30	2003-04-29	Pfizer Inc	Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
MXPA00006605A (es) *	1999-07-02	2004-12-09	Pfizer	Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
ATE225785T1 (de) *	1999-07-02	2002-10-15	Pfizer	Tetrazolylalkyl-indolderivate als entzündungshemmende und analgetische mittel
CO5261556A1 (es)	1999-12-08	2003-03-31	Pharmacia Corp	Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
AU2003299757A1 (en) *	2002-12-19	2004-07-14	Elan Pharmaceuticals Inc.	Substituted n-phenyl sulfonamide bradykinin antagonists
US7098231B2 (en)	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
ATE342722T1 (de)	2003-05-07	2006-11-15	Osteologix As	Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
KR100795462B1 (ko)	2006-09-27	2008-01-16	한국생명공학연구원	인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
EP2114895A4 (fr)	2006-10-17	2011-06-22	Stiefel Laboratories	Métabolites de talarazole
US20120022121A1 (en) *	2007-11-29	2012-01-26	Dalton James T	Indoles, derivatives and analogs thereof and uses therefor
WO2011133442A1 (fr) *	2010-04-19	2011-10-27	Metabolic Solutions Development Company	Nouvelle synthèse de thiazolidinediones
JP5827326B2 (ja)	2010-07-07	2015-12-02	アーデリクス，インコーポレーテッド	リン酸輸送を阻害する化合物及び方法
EP2590656B1 (fr)	2010-07-07	2017-11-15	Ardelyx, Inc.	Composés et procédés permettant d'inhiber le transport du phosphate
EP2590965B1 (fr)	2010-07-07	2016-04-20	Ardelyx, Inc.	Composés et procédés pour l'inhibition du transport de phosphate
JP5827328B2 (ja)	2010-07-07	2015-12-02	アーデリクス，インコーポレーテッド	リン酸輸送を阻害する化合物及び方法
RU2594725C2 (ru)	2010-08-10	2016-08-20	МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи	Синтез соединений тиазолидиндиона
WO2012021476A1 (fr)	2010-08-10	2012-02-16	Metabolic Solutions Development Company, Llc	Nouvelle synthèse pour des composés de thiazolidinedione
WO2013138600A1 (fr) *	2012-03-16	2013-09-19	Rosen Eliot M	Composés radioprotecteurs
US9808443B1 (en)	2016-11-28	2017-11-07	King Saud University	Cyclooxygenase inhibitors
CN111004121A (zh) *	2019-12-09	2020-04-14	南京杰运医药科技有限公司	一种4-烷氧基乙酰乙酸酯类化合物的制备方法
CN112409281B (zh) *	2020-08-20	2022-11-18	上海大学	(e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
US20240165148A1 (en)	2021-03-15	2024-05-23	Saul Yedgar	Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
JP7759065B2 (ja) *	2021-06-10	2025-10-23	延世大学校産学協力団	ペンドリン抑制活性を有する新規化合物およびその医薬用途
CN116262721B (zh) *	2023-01-12	2026-03-13	浙江师范大学	一种二氢吲哚衍生物及吲哚衍生物的制备方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5604253A (en) *	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) *	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CO5190664A1 (es) *	1999-06-30	2002-08-29	Pfizer Prod Inc	Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2

1998
- 1998-12-17 AP APAP/P/1998/001423A patent/AP869A/en active
- 1998-12-18 CN CN98813530A patent/CN1284064A/zh active Pending
- 1998-12-18 US US09/355,494 patent/US6608070B1/en not_active Expired - Fee Related
- 1998-12-18 EA EA200000614A patent/EA200000614A1/ru unknown
- 1998-12-18 ES ES98959082T patent/ES2255190T3/es not_active Expired - Lifetime
- 1998-12-18 WO PCT/IB1998/002065 patent/WO1999035130A1/fr not_active Ceased
- 1998-12-18 KR KR10-2000-7007419A patent/KR100404054B1/ko not_active Expired - Fee Related
- 1998-12-18 ID IDW20001286A patent/ID24876A/id unknown
- 1998-12-18 AT AT98959082T patent/ATE308519T1/de not_active IP Right Cessation
- 1998-12-18 JP JP2000527531A patent/JP3347136B2/ja not_active Expired - Fee Related
- 1998-12-18 SK SK991-2000A patent/SK9912000A3/sk unknown
- 1998-12-18 HR HR20000454A patent/HRP20000454A2/hr not_active Application Discontinuation
- 1998-12-18 AU AU15005/99A patent/AU748107B2/en not_active Ceased
- 1998-12-18 TR TR2000/01906T patent/TR200001906T2/xx unknown
- 1998-12-18 YU YU41600A patent/YU41600A/sh unknown
- 1998-12-18 BR BR9813124-9A patent/BR9813124A/pt not_active IP Right Cessation
- 1998-12-18 IL IL13688598A patent/IL136885A0/xx unknown
- 1998-12-18 PL PL98341696A patent/PL341696A1/xx unknown
- 1998-12-18 CA CA002316863A patent/CA2316863A1/fr not_active Abandoned
- 1998-12-18 EP EP98959082A patent/EP1045833B1/fr not_active Expired - Lifetime
- 1998-12-18 HU HU0102922A patent/HUP0102922A3/hu unknown
- 1998-12-18 DE DE69832200T patent/DE69832200T2/de not_active Expired - Fee Related
- 1998-12-22 TW TW087120865A patent/TW436482B/zh active
- 1998-12-28 HN HN1997000098A patent/HN1997000098A/es unknown
- 1998-12-28 PE PE1998001288A patent/PE20000055A1/es not_active Application Discontinuation
- 1998-12-29 GT GT199800205A patent/GT199800205A/es unknown
- 1998-12-30 CO CO98077588A patent/CO4970807A1/es unknown
- 1998-12-31 UY UY25332A patent/UY25332A1/es not_active IP Right Cessation
1999
- 1999-01-04 TN TNTNSN99001A patent/TNSN99001A1/fr unknown
- 1999-01-04 DZ DZ990001A patent/DZ2700A1/fr active
- 1999-01-04 AR ARP990100010A patent/AR016977A1/es not_active Application Discontinuation
- 1999-01-04 MA MA25414A patent/MA24736A1/fr unknown
- 1999-01-04 ZA ZA9900011A patent/ZA9911B/xx unknown
- 1999-01-05 PA PA19998466201A patent/PA8466201A1/es unknown
- 1999-04-13 SA SA99191299A patent/SA99191299A/ar unknown
- 1999-06-28 UY UY25590A patent/UY25590A1/es not_active Application Discontinuation
2000
- 2000-06-13 IS IS5532A patent/IS5532A/is unknown
- 2000-06-30 OA OA1200000195A patent/OA11441A/en unknown
- 2000-07-04 NO NO20003451A patent/NO20003451L/no unknown
- 2000-07-28 BG BG104643A patent/BG104643A/bg unknown

Also Published As

Publication number	Publication date
TNSN99001A1 (fr)	2005-11-10
HUP0102922A2 (hu)	2001-12-28
TW436482B (en)	2001-05-28
GT199800205A (es)	2000-06-21
IL136885A0 (en)	2001-06-14
DE69832200D1 (de)	2005-12-08
IS5532A (is)	2000-06-13
SA99191299A (ar)	2005-12-03
BR9813124A (pt)	2000-10-10
OA11441A (en)	2004-04-27
AP869A (en)	2000-09-04
CO4970807A1 (es)	2000-11-07
WO1999035130A1 (fr)	1999-07-15
MA24736A1 (fr)	1999-10-01
PE20000055A1 (es)	2000-02-08
KR100404054B1 (ko)	2003-11-01
JP3347136B2 (ja)	2002-11-20
EA200000614A1 (ru)	2001-02-26
HUP0102922A3 (en)	2003-06-30
NO20003451D0 (no)	2000-07-04
ES2255190T3 (es)	2006-06-16
YU41600A (sh)	2003-08-29
ZA9911B (en)	2000-07-04
PL341696A1 (en)	2001-04-23
HN1997000098A (es)	1998-12-28
DE69832200T2 (de)	2006-04-20
JP2002500217A (ja)	2002-01-08
CA2316863A1 (fr)	1999-07-15
TR200001906T2 (tr)	2001-01-22
KR20010033859A (ko)	2001-04-25
AU748107B2 (en)	2002-05-30
SK9912000A3 (en)	2001-11-06
HRP20000454A2 (en)	2001-04-30
DZ2700A1 (fr)	2003-09-01
ID24876A (id)	2000-08-31
US6608070B1 (en)	2003-08-19
NO20003451L (no)	2000-09-01
UY25332A1 (es)	2001-01-31
EP1045833B1 (fr)	2005-11-02
CN1284064A (zh)	2001-02-14
AR016977A1 (es)	2001-08-01
PA8466201A1 (es)	2000-09-29
ATE308519T1 (de)	2005-11-15
UY25590A1 (es)	1999-09-27
AU1500599A (en)	1999-07-26
AP9801423A0 (en)	1998-12-31
EP1045833A1 (fr)	2000-10-25

Publication	Publication Date	Title
AU748107B2 (en)	2002-05-30	2,3-substituted indole compounds as COX-2 inhibitors
JP3333179B2 (ja)	2002-10-07	抗炎症／鎮痛薬としての二環式カルボニルインドール化合物
EP1104760B1 (fr)	2003-03-12	Composés de sulfamoylhétéroaryl-pyrazole comme analgésiques et agents anti-inflammatoires
JP3256526B2 (ja)	2002-02-12	抗炎症および鎮痛剤としての置換インドール化合物
ES2208227T3 (es)	2004-06-16	Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
US6294558B1 (en)	2001-09-25	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
CZ20002455A3 (cs)	2001-03-14	2,3-Substituované indoly, farmaceutické kompozice na jejich bázi, způsob léčení a způsoby výroby
JP3337209B2 (ja)	2002-10-21	抗炎症および鎮痛薬としてのテトラゾリルアルキルインドール化合物
US6727238B2 (en)	2004-04-27	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
HK1033670A (en)	2001-09-14	2,3-substituted indole compounds as cox-2 inhibitors